Really interesting McKinsey article about realworld evidence - courtesy of @Melissa_Barry - interesting about who else is connecting records together (Japan, US, France, UK).
Question I have is about how deep or rich the data is about the population covered - wondering if in the US at least it is mainly insurance focused…
There are companies like TriNetX (https://www.trinetx.com/company-overview/) and IQVIA (https://www.iqvia.com/about-us/iqvia-core) which assemble data from multiple sources internationally, including providers and insurers.
opengraphobject:[351561245108085 : https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making : title=“Real-world evidence: From activity to impact in healthcare decision making | McKinsey & Company” : description=“While there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders.”], opengraphobject:[351561245265767 : https://www.trinetx.com/company-overview/ : title=“The Global Health Research Network” : description=“”], opengraphobject:[351561245265866 : https://www.iqvia.com/about-us/iqvia-core : title=“IQVIA CORE™ - IQVIA” : description=“”]
That is interesting for IQVIA it appears their focus is clinical trials - I think the McKinsey article is suggesting the opposite - if we connect the systems operationally maybe we get all the data we need for research -as long as we can anonymise/consent the participants…
opengraphobject:[351561245108085 : https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making : title=“Real-world evidence: From activity to impact in healthcare decision making | McKinsey & Company” : description=“While there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders.”]
While it definitely includes clinical trials as a potential market, IQVIA seems to recognise many further applications for their enormous database, including diagnostic, operational, predictive, and motivational/adherence uses. Their very existence is due to the fact that so much data is already being collected: they are an international data consolidator. In NZ, the NHI provides a connection mechanism. For research purposes, the IDI is another massive asset, particularly when joined up with further health data.
To me, a really interesting area to explore is how information can be supplied in user-friendly applications to enable more effective citizen/whanau/community engagement to manage their own well-being.
opengraphobject:[351561245108085 : https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making : title=“Real-world evidence: From activity to impact in healthcare decision making | McKinsey & Company” : description=“While there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders.”]
It is also worth bearing in mind that McKinsey is focused on creating value for their customers, namely providers, payers, and pharma (not consumers).
opengraphobject:[351561245108085 : https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making : title=“Real-world evidence: From activity to impact in healthcare decision making | McKinsey & Company” : description=“While there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders.”]